Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19826412 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Lucs AV, Muller WJ, Muthuswamy SK (2010) Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene 29, 174-87 19826412
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y1141-p - HER2 (rat)
Orthologous residues
HER2 (human): Y1139‑p, HER2 iso2 (human): Y529‑p, HER2 (mouse): Y1140‑p, HER2 (rat): Y1141‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDCK (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  dog, human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE HER2 (rat) pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AP1510 increase

Y1198-p - HER2 (rat)
Orthologous residues
HER2 (human): Y1196‑p, HER2 iso2 (human): Y586‑p, HER2 (mouse): Y1197‑p, HER2 (rat): Y1198‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDCK (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  dog, human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE HER2 (rat) pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AP1510 increase

Y1223-p - HER2 (rat)
Orthologous residues
HER2 (human): Y1221‑p, HER2 iso2 (human): Y611‑p, HER2 (mouse): Y1222‑p, HER2 (rat): Y1223‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDCK (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  dog, human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE HER2 (rat) pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AP1510 increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  apoptosis, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Shc1 (human) Disrupts co-immunoprecipitation
 Comments:  inhibits apoptosis

Y1224-p - HER2 (rat)
Orthologous residues
HER2 (human): Y1222‑p, HER2 iso2 (human): Y612‑p, HER2 (mouse): Y1223‑p, HER2 (rat): Y1224‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDCK (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  dog, human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE HER2 (rat) pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AP1510 increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  apoptosis, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Shc1 (human) Disrupts co-immunoprecipitation
 Comments:  inhibits apoptosis

Y1250-p - HER2 (rat)
Orthologous residues
HER2 (human): Y1248‑p, HER2 iso2 (human): Y638‑p, HER2 (mouse): Y1249‑p, HER2 (rat): Y1250‑p
Characterization
 Methods used to characterize site in vivo flow cytometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell), MDCK (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  dog, human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE HER2 (rat) pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AP1510 increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.